Could a Triple-Drug cocktail prevent multiple myeloma?

This phase 2 pilot study tested a combination of three drugs—carfilzomib, lenalidomide, and dexamethasone—in 55 people with high-risk smoldering multiple myeloma, a condition that often leads to active myeloma. The goal was to see if the treatment could eliminate signs of the disease in the bone marrow (minimal residual disease) and delay progression. Participants received eight 28-day cycles of all three drugs, followed by up to 12 more cycles of lenalidomide alone if their disease did not worsen.